Related Experiment Video

Updated: Dec 9, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.9K

The impact of infection with hepatitis C virus on cardiovascular risk

Roua A Iorga1, Nicolae Bacalbasa2,3, Ovidiu G Bratu2,4,5

  • 1Clinical Emergency Hospital of Bucharest Bucharest, Romania.

American Journal of Cardiovascular Disease
|September 14, 2020
PubMed

Insights

Chronic hepatitis C virus (HCV) infection is a systemic disease impacting cardiovascular and metabolic health. Early treatment can mitigate serious complications like liver cirrhosis and heart disease.

Area of Science:

  • Hepatology
  • Cardiology
  • Endocrinology

Background:

  • Chronic hepatitis C virus (HCV) infection progresses beyond liver damage.
  • HCV infection is linked to systemic issues including endothelial dysfunction, oxidative stress, and insulin resistance.
  • These systemic effects are recognized as significant cardiovascular risk factors.

Purpose of the Study:

  • To provide an overview of systemic alterations in chronic HCV infection.
  • To emphasize the cardiovascular and metabolic effects of HCV.
  • To highlight HCV as a treatable disease with significant health impacts.

Main Methods:

  • Literature review of systemic manifestations in chronic HCV infection.
  • Analysis of cardiovascular and metabolic consequences.
  • Focus on prevalent and important systemic alterations.

Main Results:

  • Chronic HCV infection leads to hepatic steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma.
  • Systemic manifestations include endothelial dysfunction, atherosclerosis, oxidative stress, insulin resistance, and immunological alterations.
  • HCV is associated with increased risk of type 2 diabetes mellitus, stroke, coronary artery disease, and heart failure.

Conclusions:

  • Chronic HCV infection is a systemic disease with profound cardiovascular and metabolic implications.
  • Systemic alterations associated with HCV significantly impact morbidity and mortality.
  • Recognizing and treating HCV is crucial for managing associated systemic complications.

Keywords:
Hepatitis C viruscardiovascular riskdiabetes mellitusinsulin resistancemetabolic syndrome

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
127
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
240
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
102
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
721
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
3.7K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
105